Trial · NCT01988402
Does Allopurinol Prolong a Treated, Acute Gout Flare?
NCT01988402, Phase 4, Completed, 59th Medical Wing; results first posted 2015-01-05
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Does Allopurinol Prolong a Treated, Acute Gout Flare? Trials, record NCT01988402. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01988402
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Does Allopurinol Prolong a Treated, Acute Gout Flare?
- NCT number
- NCT01988402
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 35 participants, actual
- Lead sponsor
- 59th Medical Wing
- Conditions
- Gout
- Interventions
- allopurinol, Placebo (sugar pill)
- First posted
- 2013-11-20
- Last updated
- 2018-02-14
- Results first posted
- 2015-01-05
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Resolution of the Acute Gout Attack | 1-28 Days | The primary outcome unit of measurement is time (in days) to resolution of the acute gout attack |
| Secondary | Pain Day 28 | Pateints are assessed at five time intervals over 28 days: days 1, 3-4, 10-15, 20-25, and 28; Day 28 reported | Patient rated pain on a Likert pain score of 0-10 |
| Secondary | Physician Global Assessment of Gout Activity at Day 28 | Pateints are assessed at five time intervals over 28 days: days 1, 3-4, 10-15, 20-25, and 28; Day 28 reported | Physician rated gout activity is measured on a Likert scale 0-10. |
| Secondary | Serum Uric Acid Level | day 28 | Blood test (serum) for uric acid level |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Resolution of the Acute Gout Attack | 1-28 Days | days | MEAN | |
| SECONDARY | Pain Day 28 | Pateints are assessed at five time intervals over 28 days: days 1, 3-4, 10-15, 20-25, and 28; Day 28 reported | units on a Likert scale | MEAN | |
| SECONDARY | Physician Global Assessment of Gout Activity at Day 28 | Pateints are assessed at five time intervals over 28 days: days 1, 3-4, 10-15, 20-25, and 28; Day 28 reported | units on a Likert scale | MEAN | |
| SECONDARY | Serum Uric Acid Level | day 28 | mg/dl | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Resolution of the Acute Gout Attack | Allopurinol | 15.4 | Standard Deviation 7.9 | days | |
| Resolution of the Acute Gout Attack | Sugar Pill (Placebo) | 13.4 | Standard Deviation 7.8 | days | |
| Pain Day 28 | Allopurinol | 1.79 | 95% Confidence Interval 0 to 4 | units on a Likert scale | |
| Pain Day 28 | Sugar Pill (Placebo) | 2.0 | 95% Confidence Interval 0 to 4 | units on a Likert scale | |
| Physician Global Assessment of Gout Activity at Day 28 | Allopurinol | 0 | 95% Confidence Interval 0 to 0 | units on a Likert scale | |
| Physician Global Assessment of Gout Activity at Day 28 | Sugar Pill (Placebo) | 0 | 95% Confidence Interval 0 to 0 | units on a Likert scale | |
| Serum Uric Acid Level | Allopurinol | 6.4 | Standard Error 1.0 | mg/dl | |
| Serum Uric Acid Level | Sugar Pill (Placebo) | 8.2 | Standard Error 1.0 | mg/dl |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Allopurinol | 16 | |
| Overall Study | STARTED | Sugar Pill (Placebo) | 19 | |
| Overall Study | COMPLETED | Allopurinol | 14 | |
| Overall Study | COMPLETED | Sugar Pill (Placebo) | 17 | |
| Overall Study | NOT COMPLETED | Allopurinol | 2 | |
| Overall Study | NOT COMPLETED | Sugar Pill (Placebo) | 2 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | epistaxis | Respiratory, thoracic and mediastinal disorders | Allopurinol | 1 | 16 | 1 |
| serious | epistaxis | Respiratory, thoracic and mediastinal disorders | Sugar Pill (Placebo) | 0 | 19 | 0 |
| serious | elevated liver enzymes | Gastrointestinal disorders | Allopurinol | 0 | 16 | |
| serious | elevated liver enzymes | Gastrointestinal disorders | Sugar Pill (Placebo) | 1 | 19 | |
| serious | nausea and vomiting | Gastrointestinal disorders | Allopurinol | 0 | 16 | |
| serious | nausea and vomiting | Gastrointestinal disorders | Sugar Pill (Placebo) | 1 | 19 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Allopurinol | ||
| Total, all-cause mortality | Sugar Pill (Placebo) | ||
| Total, other adverse events | Allopurinol | 0 | 16 |
| Total, other adverse events | Sugar Pill (Placebo) | 0 | 19 |
| Total, serious adverse events | Allopurinol | 1 | 16 |
| Total, serious adverse events | Sugar Pill (Placebo) | 2 | 19 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Allopurinol vs Sugar Pill (Placebo): serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01988402
GET https://conductscience.org/api/trials/v1/NCT01988402/registered